1 to 2 of 2 literature results

• Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

  OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this study was to assess the effect of 10 mg of atorvasta…

  Authors: Robert H Knopp, Michael d'Emden, Johan G Smilde, Stuart J Pocock

  Source: Diabetes care. 2006 Jul

  View Full Text

• Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  OBJECTIVE: We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndro…

  Authors: Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael D'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

  Source: Diabetes care. 2009 Mar

  View Free Full Text